Individual CD19⁺ B cells in the 300-mg (A), 500-mg (B), 700-mg (C), and 1000-mg (D) dose groups. Red triangles represent days of ofatumumab infusions. Written values in the top of panels B and C are outliers. One patient in the 500-mg group (B) was withdrawn at visit 2; hence, data from 9 patients only are presented. The median CD19⁺ count at baseline was 85 × 10⁶/L (range, 7-939). Most patients had a profound depletion of CD19⁺ cells after the first infusion lasting 6 to 10 months followed by a slow gradual recovery.